Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

12,083 total articles

GoDaddy Officer Sells Shares Amid AI Expansion and Earnings Beat

GoDaddy Officer Sells Shares Amid AI Expansion and Earnings Beat

Palitwanon Phontip, Chief Accounting Officer at GoDaddy Inc., recently sold a small number of company shares. This transaction occurred while the firm reported strong first-quarter earnings for 2026, surpassing revenue expectations and highlighting significant growth initiatives centered on artificial intelligence. The sale was tied to tax obligati…

GoDaddy CFO Sells Shares Amid Tax Obligations; Company Shows Signs of Growth and Strategic Investment

GoDaddy CFO Sells Shares Amid Tax Obligations; Company Shows Signs of Growth and Strategic Investment

Chief Financial Officer Mark McCaffrey recently sold a portion of his company stock for $1,426. This sale was executed to cover tax withholding related to shares acquired through the 2024 Employee Stock Purchase Plan. Despite this transaction, GoDaddy has demonstrated strong operational performance, reporting Q1 2026 EPS of $1.60 and revenue of $1.…

Ameresco Director Sells Stock Following Recent Gains; Company Reports Major Partnerships and Strong Earnings

Ameresco Director Sells Stock Following Recent Gains; Company Reports Major Partnerships and Strong Earnings

Director Jennifer L. Miller sold 10,000 shares of Ameresco's Class A Common Stock on May 18, 2026, totaling $322,714. The sales occurred after the stock had appreciated significantly over the past year but subsequently pulled back to $28.93. Separately, the company reported robust first-quarter revenue and announced a major biofuels joint venture t…

Eos Energy Director Sells Shares Amid Price Volatility; Q1 Earnings Report Highlights Operational Performance

Eos Energy Director Sells Shares Amid Price Volatility; Q1 Earnings Report Highlights Operational Performance

Director Marian Walters sold a portion of Eos Energy Enterprises stock on May 19, 2026, while also acquiring shares through option exercises and RSU vesting. This activity occurred as the company's stock faced recent declines. Separately, Eos reported Q1 2026 financial results, posting an earnings per share (EPS) of $0.12, significantly beating exp…

Director Aidan Gomez's Transactions at Rivian Highlight Internal Activity Amid Financial Mixed Signals

Director Aidan Gomez's Transactions at Rivian Highlight Internal Activity Amid Financial Mixed Signals

Rivian director Aidan N. Gomez executed significant transactions involving the company's stock in May 2026. While Mr. Gomez purchased shares totaling $251,460, his direct ownership was also reduced by a tax-related disposition of 3,752 shares. These personal movements occurred amidst mixed corporate signals for Rivian Automotive: the company report…

Applied Optoelectronics CFO's Transactions Highlight Valuation Concerns Amid Mixed Earnings Signals

Applied Optoelectronics CFO's Transactions Highlight Valuation Concerns Amid Mixed Earnings Signals

The recent activity of Applied Optoelectronics' Chief Financial Officer, Stefan J. Murry, involving both significant sales and acquisitions of common stock, comes against a backdrop of fluctuating market sentiment for AAOI. The CFO disposed of shares totaling over $5.7 million last week. This insider movement occurs as the stock trades at $171.41, …

Tenaya Therapeutics' Stock Activity and Pipeline Developments Signal Continued Focus on Gene Therapies

Tenaya Therapeutics' Stock Activity and Pipeline Developments Signal Continued Focus on Gene Therapies

The recent sale of common stock by Tenaya Therapeutics CEO, Ali Faraz, occurred against a backdrop of strong clinical progress and favorable analyst coverage. The company's pipeline includes promising results from the RIDGE-1 trial for TN-401 gene therapy and preclinical data supporting its HDAC6 inhibitor, TN-301. These developments highlight ongo…